Last update Jan. 15, 2022

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside

Compatible

Safe product and/or breastfeeding is the best option.

Flavonoid compound. Rutin or rutoside is a derivative of quercetin (AESAN 2012). Flavonoids are phenolic compounds naturally occurring that are abundantly present in all plants and in some seaweed.

They are ingested when drinking fruits, vegetables, tea and red wine, for example. (Serafini 1996)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. 

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012, AESAN 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins) and prevention of arteriosclerosis. 

They appear naturally in the breast milk in amounts related to mother's diet. (Romaszko 2014, Song 2013)

No risk for toxic nor side-effects in humans have been found (AESAN 2012). No problems have been observed in infants whose mothers were treated with troxerutin. (Krajnovic 1977)

 

The maximum acceptable daily intake amount for rutin is 150 mg. (AESAN 2012)


See below the information of this related product:

  • Quercetin (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside is Rutoside in Chemical name.

Is written in other languages:

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside is also known as

Groups

2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside belongs to these groups or families:

Tradenames

Main tradenames from several countries containing 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition:

  • Energyvit™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Epistaxol solución cutánea™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Fortavil™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Pharmaton Complex (Mexico)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Phlogenzym™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Phlogenzym (Флогэнзим)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Quadevit (Квадевит)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Trimedal™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Wobenzym (Germany)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Wobenzym (Austria, Mexico, Czech Republic)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Wobenzym (Вобэнзим)™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition
  • Wobenzym N™. Contains other elements than 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4-oxo-4H-chromen-3-yl rutinoside trihydrate; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(α-l-rhamnosyl)-β-d-glucoside in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 %
Molecular weight 611 daltons
pKa 6.43 -
Tmax 7 - 10 hours
6 - 34 hours

References

  1. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Abstract
  2. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015 Abstract
  3. Romaszko E, Wiczkowski W, Romaszko J, Honke J, Piskula MK. Exposure of breastfed infants to quercetin after consumption of a single meal rich in quercetin by their mothers. Mol Nutr Food Res. 2014 Abstract
  4. AESAN. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) sobre condiciones de uso de determinadas sustancias distintas de vitaminas, minerales y plantas para ser empleadas en complementos alimenticios - 1. Revista del comité científico nº 17. 2012 Full text (in our servers)
  5. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012 Abstract
  6. Jaganath IB, Mullen W, Edwards CA, Crozier A. The relative contribution of the small and large intestine to the absorption and metabolism of rutin in man. Free Radic Res. 2006 Abstract
  7. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002 Abstract
  8. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr. 1996 Abstract
  9. Krajnovic P. [The influence of the combination of coumarin and troxerutin on infantile blood parameter in lactation period. Short communication (author's transl)]. Arzneimittelforschung. 1977 Abstract

Total visits

2,567

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM